# Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine

> **NCT01867463** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 230 (actual)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** Pfs25-EPA/Alhydrogel
- **BIOLOGICAL:** Euvax B
- **BIOLOGICAL:** Menactra

## Key facts

- **NCT ID:** NCT01867463
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-27
- **Primary completion:** 2015-12-22
- **Final completion:** 2016-12-19
- **Target enrollment:** 230 (ACTUAL)
- **Last updated:** 2018-07-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01867463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01867463, "Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01867463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*